Literature DB >> 20729116

["Dose-painting": myth or reality?].

S Supiot1, A Lisbona, F Paris, D Azria, P Fenoglietto.   

Abstract

"Dose-painting" radiotherapy allows for a heterogeneous delivery of radiation within the tumour volume by targeting radioresistant areas defined by functional imaging. Within gross tumour volume, it is possible to define one or more target volumes based on biology (biological target volume [BTV]) and to apply a strategy of intensity modulated radiation therapy (IMRT) that will deliver a higher dose to these regions. In this review of the literature, we will highlight the biological elements responsible for radioresistance, and how to image them, then we will detail the radiotherapy techniques necessary for this approach, before presenting clinical results in various situations (head and neck tumours, prostate, brain tumours, etc.). Despite many difficulties that make dose-painting IMRT unusable in routine nowadays, biology-guided radiation therapy represents one of the major pathways of development of radiotherapy in the coming years.
Copyright © 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20729116     DOI: 10.1016/j.canrad.2010.06.005

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  4 in total

1.  A Prospective Investigation of Tumor Hypoxia Imaging with 68Ga-Nitroimidazole PET/CT in Patients with Carcinoma of the Cervix Uteri and Comparison with 18F-FDG PET/CT: Correlation with Immunohistochemistry.

Authors:  Kgomotso M G Mokoala; Ismaheel O Lawal; Letjie C Maserumule; Khanyisile N Hlongwa; Honest Ndlovu; Janet Reed; Meshack Bida; Alex Maes; Christophe van de Wiele; Johncy Mahapane; Cindy Davis; Jae Min Jeong; Gbenga Popoola; Mariza Vorster; Mike M Sathekge
Journal:  J Clin Med       Date:  2022-02-12       Impact factor: 4.241

2.  Hypoxia imaging with 18F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts.

Authors:  Elodie Melsens; Elly De Vlieghere; Benedicte Descamps; Christian Vanhove; Ken Kersemans; Filip De Vos; Ingeborg Goethals; Boudewijn Brans; Olivier De Wever; Wim Ceelen; Piet Pattyn
Journal:  Radiat Oncol       Date:  2018-03-07       Impact factor: 3.481

3.  Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study.

Authors:  Stéphane Supiot; Caroline Rousseau; Mélanie Dore; Catherine Cheze-Le-Rest; Christine Kandel-Aznar; Vincent Potiron; Stéphane Guerif; François Paris; Ludovic Ferrer; Loïc Campion; Philippe Meingan; Gregory Delpon; Mathieu Hatt; Dimitris Visvikis
Journal:  Oncotarget       Date:  2018-01-13

4.  Locoregional Confinement and Major Clinical Benefit of 188Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma.

Authors:  Delphine Séhédic; Igor Chourpa; Clément Tétaud; Audrey Griveau; Claire Loussouarn; Sylvie Avril; Claire Legendre; Nicolas Lepareur; Didier Wion; François Hindré; François Davodeau; Emmanuel Garcion
Journal:  Theranostics       Date:  2017-10-12       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.